Sargent Investment Group LLC Invests $263,000 in ChromaDex Co. (NASDAQ:CDXC)

Sargent Investment Group LLC bought a new position in ChromaDex Co. (NASDAQ:CDXC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $263,000. Sargent Investment Group LLC owned approximately 0.07% of ChromaDex as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CDXC. USA Financial Formulas purchased a new stake in shares of ChromaDex during the fourth quarter worth $25,000. The Manufacturers Life Insurance Company acquired a new position in ChromaDex in the 2nd quarter worth about $31,000. FMR LLC purchased a new stake in shares of ChromaDex during the 3rd quarter worth about $55,000. Marshall Wace LLP acquired a new stake in shares of ChromaDex during the 2nd quarter valued at about $56,000. Finally, SG Americas Securities LLC bought a new stake in shares of ChromaDex in the 3rd quarter valued at approximately $61,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CDXC. HC Wainwright raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, November 4th. StockNews.com downgraded shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Wednesday, January 15th. Finally, Roth Mkm upped their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th.

Insider Activity

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 9.64% of the company's stock.

ChromaDex Price Performance

CDXC traded down $0.17 on Friday, hitting $5.52. The company had a trading volume of 233,899 shares, compared to its average volume of 312,324. The stock has a market cap of $421.62 million, a price-to-earnings ratio of 552.55 and a beta of 2.21. The company's fifty day moving average price is $5.87 and its 200 day moving average price is $4.76. ChromaDex Co. has a 1-year low of $1.46 and a 1-year high of $7.97.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.